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with rituximab iv preparation and administration, per treatment cycle, was about 89 
minutes versus 16 minutes estimated for sc. An average overall cost reduction of 93% 
was estimated with sc versus iv (3€ versus 45€ , respectively). DCU chair time capacity 
could be increased by 3 and 7 fold if one considers combination or maintenance 
therapy, respectively, with rituximab sc versus iv, due to SC much faster administra-
tion. Rituximab sc reduces the overall time patients spend in an infusion chair by 
95% (7 min with sc vs.143 min with iv). ConClusions: Rituximab sc formulation 
potentially offers significant resource (material and HCP time) savings, improves 
hospital organization and provides clear benefits for patients regarding time saved 
and administration convenience. Ultimately, rituximab sc increases hospital effi-
ciency that’s critical in the current economic climate.
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objeCtives: Pain is an important driver of health-related utility. Our purpose was to 
characterise the association between pain severity and the EQ-5D index. Methods: 
Paired values for the Numerical Pain Rating Scale (NPRS) average pain score (previ-
ous 24 hours) and the EQ-5D index were available from a prospective, non-inter-
ventional study of people with neuropathic pain treated with an 8% capsaicin patch 
(QutenzaTM). The NPRS records pain on an integer scale between 0 and 10 units, 
representing no pain and worst imaginable pain, respectively. The EQ-5D index 
is derived from impairment level (none/moderate/severe) across five domains 
(Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), and 
values health-related utility on a scale of 1 to 0, meaning perfect health and death, 
respectively. Generalized linear mixed models with a normal probability distribu-
tion, identity link function, and a first-order autoregressive covariance structure 
were tested to determine the relationship between EQ-5D index score (scale) and 
NPRS average 24 hour pain score (ordinal). Results: For the purposes of this pre-
liminary analysis, 170 patients with NP contributed 353 combined observations from 
baseline observation and follow-up assessments at week-8 and week-12. The GLMM 
model that best fitted the data (smallest Information criterion) had one random 
effect (subject + intercept) and one fixed effect (NPRS + intercept). The fixed-effects 
coefficients were: (Intercept) 0.728 + (NPRS1: β 0.000; 95%CI -0.0186, 0.186) + (NPRS2: 
-0.045;-0.205,0.116) + (NPRS3: -0.075;-0.227,0.078) + (NPRS4: -0.207;-0.364,-0.049) + 
(NPRS5: -0.181;-0.338,-0.024) + (NPRS6: -0.315;-0.471,-0.159) + (NPRS7: -0.323;-0.478,-
0.167) + (NPRS8: -0.458;-0.618,-0.299) + (NPRS9: -0.638;-0.825,-0.451) + (NPRS10: -0.740; 
-0.927,-0.553). Predicted utility was highly correlated (R2= 0.753) with observed util-
ity. Mean squared error for predicted utility was 0.033 (sd 0.052). ConClusions: 
Neuropathic pain was highly correlated with utility with a difference of around 
0.8 utility units across the NPRS range. All domains of the EQ-5D differed across 
the NPRS.
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objeCtives: Health care payers are interested in funding bariatric surgery because 
it resolves a range of obesity-related health problems. However, following weight 
loss, many patients are left with unsightly excesses of skin and require body-con-
touring surgery. Our team has developed a new PRO instrument (i.e., the BODY-Q) 
to measure satisfaction and quality of life of bariatric and body-contouring surgery 
patients. Unlike existing PRO instruments, the BODY-Q is composed of scales that 
measure appearance-related concerns, which is an important reason why patients 
seek treatment. The BODY-Q also stands apart as it the only PRO instrument designed 
to measure change in patients concerns throughout the entire weight loss jour-
ney. Methods: We followed international guidelines for the development of a PRO 
instrument. This abstract presents Phase I results, i.e., qualitative phase. Patient 
stories were used to develop a conceptual framework covering the key concerns of 
patients, and to develop a set of preliminary items. Items were grouped into clinically 
meaningful scales and instructions and four-point response options were developed. 
The scales were refined by obtaining feedback from a sample of surgical experts and 
patients. Results: From 59 patient interviews, we developed a conceptual frame-
work. Over 3,500 preliminary items were developed and used to inform the following 
17 independently functioning scales: 1) appearance scales measuring the body, abdo-
men, upper arms, buttocks, inner thighs, hip and outer thighs, skin and scars; 2) qual-
ity of life scales measuring body image, sexual, psychological and social wellbeing, 
physical function and symptoms; and 3) process of care scales measuring satisfaction 
with information, doctor and office staff. ConClusions: Phase II involves a multi-
centered field-test in Canada and the USA. Rasch Measurement Theory analysis will 
be used to determine which items to retain in each scale based on their performance 
against a standard set of psychometric criteria.
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its ethical and social values, supplies plasma at a lower or comparable cost than 
commercially available.
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objeCtives: To estimate indirect costs of systemic lupus erythematosus (SLE) in 
Poland, based on absenteeism in the workplace data derived from Department of 
Statistics of the Social Insurance Institution (ZUS). Methods: Available insurance 
information consisted of data on: (1) sick leaves, (2) short-term inability to work - on 
the basis of decisions authorizing rehabilitation services (3) long-term inability to 
work – on the basis of medical certificates awarded because of incapacity for work. 
To calculate indirect costs we used three parallel alterations of the human capital 
approach (HCA) method - based on: the average monthly gross earnings, Gross 
Domestic Product (GDP) per capita or gross value added per 1 employee (adjusted 
by a factor of marginal productivity of labor). Results: In 2010, in patients with SLE 
in Poland, sick leaves, short-term and long-term inability to work were responsible 
for: 1897, 596 and 27 012 months of absenteeism, in 1600, 112 and 2481 persons, 
respectively. The total number of 2459 years of lost productivity corresponded to 
indirect costs of: 100,421,579 PLN, 97,215,041 PLN or 161,743,804 PLN, based on 
average earnings, GDP per capita or adjusted gross value added per employee, 
respectively. ConClusions: Two of the three approaches, in addition - the most 
frequently mentioned in the literature, indicated the indirect costs of systemic lupus 
erythematosus in Poland at around 100 million PLN per year. Our estimates of indi-
rect costs may be undervalued because it did not include the cost of lost productivity 
due to premature mortality in the course of SLE, and the costs associated with a 
reduction in the efficiency of the work done despite of the disease (preseenteism).
PSy49
chArActerizing DiSeASe BurDen in An ultrA-rAre DiSeASe in 
the uniteD StAteS: trAnSthyretin (ttr) AmyloiDoSiS PAtientS & 
cAregiverS
Stewart M.1, Loftus J.2, Lenderking W.R.3, Murphy B.R.3, Alvir J.4, Roberts L.5, Shaffer S.5, 
Cicchetti M.J.6, Gleeson S.5
1Pfizer, Inc, Groton, CT, USA, 2Pfizer Ltd., Tadworth, UK, 3Evidera, Lexington, MA, USA, 4Pfizer, 
Inc., New York, NY, USA, 5Evidera, Bethesda, MD, USA, 6Pfizer, Inc., Groton, CT, USA
objeCtives: TTR amyloidosis, a progressive, degenerative ultra-rare genetic disease, 
can cause familial amyloid polyneuropathy (TTR-FAP) and cardiomyopathy (TTR-CM), 
requiring substantial caregiver support. This study evaluated the burden of illness 
on patients’ and caregivers’ work productivity, health care resource use (HCRU), and 
health-related quality of life (HRQoL). Methods: An online survey including the 
Work Productivity & Activity Impairment (WPAI) questionnaire, EQ-5D, & HCRU ques-
tions recruited TTR-FAP and TTR-CM patients and caregivers through two U.S.-based 
patient advocacy groups. Results: Thirty-three TTR patients (26 males) and 18 car-
egivers (7 males) completed the survey. Most were aged over 60; mean disease dura-
tion was approximately 6 years (patients) or 5 years (caregivers with disease). Most 
patients and caregivers had a college degree. Generally caregivers (77.8%) were the 
primary caregiver for their patient; 61.1% also had amyloidosis. Unemployment was 
high in patients with TTR-FAP (42.9%), TTR-CM (60.0%), both TTR-FAP/CM (71.4%); only 
33.3% of caregivers reported working part/full-time. Employment was highest for TTR-
FAP patients (n= 10), yet 11.8% missed work, 32.2% were impaired at work and 38.5% 
reported overall work impairment due to TTR. Liver transplant, the primary treatment 
option, occurred in 42.4% patients and 18.2% caregivers with disease. A majority of 
patients reported outpatient visits to health care providers in the past 3 months for 
disease: 85.7% TTR-FAP, 100% TTR-CM, and 85.7% for TTR-FAP/CM. Hospitalization 
rates ranged from 14.3-30.0% across all patient groups, with 14.3-23.8% for emer-
gency visits. EQ-5D Index scores for patients were 0.80 (SD= 0.14) with transplant, 
and 0.68 (SD= 0.16) without transplant. Caregivers with disease and transplant had 
lower EQ-5D Index scores (M= 0.14, SD= 0.35) than those without transplant (M= 0.41, 
SD= 0.32). The pattern was similar for EQ-5D VAS results for patient and caregiver 
groups. ConClusions: TTR amyloidosis is associated with substantial disruption 
in employment rates, work productivity, high levels of resource use, and poor HRQoL 
for patients and caregivers.
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objeCtives: Determine the costs associated with rituximab intravenous (iv) prepa-
ration and administration in follicular non-Hodgkin lymphoma (NHL) and estimate 
the difference versus rituximab subcutaneous (sc) formulation, considering material 
resources (MR) consumption and health care professionals (HCP) time spent in each 
procedure. Patient’s and chair time savings in hospital Day Care Unit (DCU) were 
also estimated. Methods: Rituximab iv data was collected, between November 
2012 and January 2013, through face to face interviews with pharmacists and DCU 
nurses responsible for the preparation and administration in each hospital. The HCP 
time cost was calculated by multiplying their income per hour by the average time 
spent on each procedure; MR costs were determined based in official databases or 
in “table values” provided by the manufacturers. Rituximab sc administration time 
was based in the respective pivotal clinical trial - SABRINA (BO22334). Results: 
Ten hospitals from mainland Portugal were included, with a weekly average of 7 
NHL patients treated with rituximab iv. The HCP average overall active time spent 
